Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 5/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.44 |
| ▸ | MPO | P05164 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103233 | 1.00 | HTR2A (0.50) | HTR2AHTR2CHTR2BIDO1CYP2C19 | |
| SCHEMBL4100325 | 0.86 | HTR2A (0.54) | HTR2AHTR2CHTR2BIDO1CYP2C19 | |
| SCHEMBL4100328 | 0.86 | HTR2A (0.54) | HTR2AHTR2CHTR2BIDO1CYP2C19 | |
| SCHEMBL3978472 | 0.83 | IDO1 (0.49) | HTR2AIDO1SLC6A4TRPM8 | |
| SCHEMBL4083580 | 0.81 | MGAM (0.49) | HTR2AHTR2CHTR2BIDO1SLC6A4 | |
| SCHEMBL4102357 | 0.80 | HTR2A (0.54) | HTR2AHTR2CHTR2BIDO1SLC6A4 | |
| SCHEMBL4102355 | 0.80 | HTR2A (0.54) | HTR2AHTR2CHTR2BIDO1SLC6A4 | |
| SCHEMBL4103244 | 0.80 | HTR2A (0.47) | HTR2AHTR2CHTR2BIDO1CYP2C19 | |
| SCHEMBL4103239 | 0.80 | HTR2A (0.47) | HTR2AHTR2CHTR2BIDO1CYP2C19 | |
| SCHEMBL4098650 | 0.77 | IDO1 (0.46) | HTR2AHTR2CHTR2BIDO1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618967-B2 | Indane compounds | H. LUNDBECK A/S (DK) | 2009-11-17 | — | — | US | disclosed |
| WO-2009106559-A1 | USES OF INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215774-A1 | USES OF INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2009-08-27 | — | — | US | disclosed |
| US-20080058329-A1 | NOVEL INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058329-A1 | NOVEL INDANE COMPOUNDS | OPRL1, HTR2C, SLC6A3 | HTR2A 15/4885HTR2C 2/4885HTR2B 36/4885 |
| US-20090215774-A1 | USES OF INDANE COMPOUNDS | GPR119, INSR, IRS1 | HTR2A 103/4885HTR2C 76/4885HTR2B 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.